Since the good representative value of ischemic heart diseases in various ischemic diseases, combination of CB2 agonist treatment with stem cell therapy is of clinical significance to treat other ischemia associated disorders in a much broader context. This evidence concerns the gene CNR2 and coronary artery disorder.